公开(公告)号：EP3233108A1

公开(公告)日：2017-10-25

申请号：EP15817678.4

申请日：2015-12-09

申请人： Eli Lilly and Company

发明人： AKERS, Michael Patrick ,  MAJUMDAR, Ranajoy ,  NGUYEN, Chi A. ,  PAAVOLA, Chad D. ,  SARIN, Virender Kumar ,  SCHULTE, Nanette Elizabeth

IPC分类号： A61K38/28 ,  A61K47/12 ,  A61P3/10

CPC分类号： A61K47/12 ,  A61K9/0019 ,  A61K38/28

摘要： The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.

摘要翻译： 本发明是人胰岛素或胰岛素类似物的组合物，其包含特定浓度的柠檬酸盐，氯化物，在一些情况下包括添加氯化钠，锌和任选的氯化镁和/或表面活性剂，并且具有更快的药代动力学和/或 药效学作用比现有胰岛素类似物产品的商业制剂。

公开(公告)号：EP4108253A1

公开(公告)日：2022-12-28

申请号：EP22164140.0

申请日：2015-12-09

申请人： Eli Lilly and Company

发明人： AKERS, Michael Patrick ,  MAJUMDAR, Ranajoy ,  NGUYEN, Chi A. ,  PAAVOLA, Chad D. ,  SARIN, Virender Kumar ,  SCHULTE, Nanette Elizabeth

IPC分类号： A61K38/28 ,  A61K47/12 ,  A61P3/10 ,  A61K9/00

摘要： The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.

公开(公告)号：EP3340966A1

公开(公告)日：2018-07-04

申请号：EP16771021.9

申请日：2016-08-19

申请人： Eli Lilly and Company

发明人： AKERS, Michael Patrick ,  CHRISTE, Michael Edward ,  HARDY, Thomas Andrew ,  MAJUMDAR, Ranajoy ,  NGUYEN, Chi A. ,  PAAVOLA, Chad D. ,  SARIN, Virender Kumar ,  SCHULTE, Nanette Elizabeth

IPC分类号： A61K9/00 ,  A61K38/28 ,  A61K47/02 ,  A61K47/12 ,  A61K31/557

CPC分类号： A61K38/28 ,  A61K9/0019 ,  A61K31/192 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/34 ,  A61K2300/00

摘要： The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.